https://biospectrumindia.com/rssfeed/suppliers/lab%20equipment%20%26%20solutions lab equipment & solutions https://biospectrumindia.com/news/117/28647/agilent-buys-proscia-for-270-m-advancing-ai-enabled-digital-pathology-and-scientific-intelligence.html https://biospectrumindia.com/news/117/28647/agilent-buys-proscia-for-270-m-advancing-ai-enabled-digital-pathology-and-scientific-intelligence.html Wed, 14 Oct 2026 13:18:37 +0530 Agilent Technologies Inc. has entered into a definitive agreement to acquire Proscia®, a provider of digital pathology software for clinical and life-sciences customers, in an all-cash transaction valued at $240 million in cash at closing and up to an additional $30 million based on achieving future performance milestones.Proscia is a leading independent provider of enterprise digital pathology software, serving as a key enabler to address emerging trends in the $5 billion Pathology market. Agilent and Proscia entered into a multi-year distribution agreement in September 2022 to offer a comprehensive digital diagnostic-pathology system. Today’s announcement builds on Agilent’s established pathology solutions and its partnership with Proscia. This acquisition strengthens Agilent's existing leadership in pathology instrumentation and reagents, combining industry-leading diagnostic capabilities with Proscia's vendor-agnostic digital pathology platform and established customer base. Proscia’s platform holds FDA 510(k) clearance for primary diagnosis.  ]]> https://biospectrumindia.com/news/117/28564/sciex-expands-biophase-8800-system-capabilities.html https://biospectrumindia.com/news/117/28564/sciex-expands-biophase-8800-system-capabilities.html Mon, 28 Sep 2026 21:29:01 +0530 SCIEX, a Danaher company and leader in life science analytical technologies, has announced new capillary electrophoresis (CE) capabilities for the BioPhase 8800 system that help laboratories accelerate development timelines, strengthen compliance, and integrate more seamlessly into automated workflows. Combining enhanced software, automation connectivity, and expanded analytical support for emerging oligonucleotide-based therapeutics, the updates give scientists greater confidence and flexibility as they move faster from development to decision. BioPhase Instrument API allows for integration of the BioPhase 8800 system into connected laboratory automation environments. External software applications can interact with the BioPhase 8800 system through remote sequence execution, real-time instrument monitoring, instrument control, and automated data acquisition. Additionally, BioPhase software 1.6 offers labs the capability to maintain flexibility for drug development with the capacity to introduce additional controls as needed to align with regulatory requirements. The software features include user management, audit trails, electronic signatures, and project management tools. ]]> https://biospectrumindia.com/news/117/28452/eppendorf-announces-launch-of-new-centrifuge-5811-r.html https://biospectrumindia.com/news/117/28452/eppendorf-announces-launch-of-new-centrifuge-5811-r.html Thu, 10 Sep 2026 15:07:32 +0530 Eppendorf has launched the new Centrifuge 5811 R, a refrigerated, multipurpose benchtop centrifuge designed to support a wide range of laboratory workflows. It builds on the proven performance and versatility of the Centrifuge 5810 R. The Centrifuge 5811 R combines a new design and a refreshed user interface with a significant update to its cooling technology. It retains the dependable performance and versatility laboratories value while adding and retains the selected new features for efficient, repeatable operation. The Centrifuge 5811 R uses R290 propane as a refrigerant. With a global warming potential of 0.02 and an ozone depletion potential of 0, this cooling technology can support laboratory sustainability goals.  With a capacity of up to 3 L and speeds of up to 20,913 x g (14,000 rpm), the Centrifuge 5811 R supports a wide range of vessel types within a single benchtop footprint.  The centrifuge supports applications including the harvesting and processing of cells, bacteria, yeast, algae and other microorganisms. It can also be used for nucleic acid and protein purification, as well as peripheral blood mononuclear cell (PBMC) isolation. The Centrifuge 5811 R is compatible with 16 of the 17 existing Centrifuge 5810 R rotors. This compatibility allows laboratories to continue using most of their existing rotor portfolio and supports a straightforward transition to the updated instrument.   ]]> https://biospectrumindia.com/news/117/28416/agilent-launches-new-laboratory-solutions-in-india.html https://biospectrumindia.com/news/117/28416/agilent-launches-new-laboratory-solutions-in-india.html Thu, 03 Sep 2026 16:05:25 +0530 Agilent Technologies has announced the India launch of the Agilent 9500 Triple Quadrupole ICP-MS, the new 8890B and 8860B Gas Chromatography Systems with GC Assist, and OpenLab Sync, Agilent's new Lab Execution System (LES) that brings guided digital workflows directly to the bench. Together, the solutions address three critical areas of laboratory operations: analytical performance, instrument productivity and workflow execution. The Agilent 9500 Triple Quadrupole ICP-MS helps laboratories generate reliable results across complex sample matrices. Designed for applications ranging from pharmaceutical testing and food safety to environmental analysis and advanced materials research, the system simplifies elemental analysis through new technologies that reduce analytical interferences and streamline operation. The new Agilent 8890B and 8860B Gas Chromatography Systems with GC Assist help laboratories keep instruments running efficiently through built-in monitoring, diagnostics and guided maintenance.  OpenLab Sync digitises laboratory procedures that are traditionally managed on paper, creating guided digital workflows that improve consistency, traceability and audit readiness.  The products were unveiled at a customer event in Mumbai that brought together scientists, laboratory leaders and quality professionals from the pharmaceutical, food, environmental, chemicals and research sectors.  ]]> https://biospectrumindia.com/news/117/28335/eppendorf-introduces-new-addition-to-research-3-neo-single-channel-pipette-line.html https://biospectrumindia.com/news/117/28335/eppendorf-introduces-new-addition-to-research-3-neo-single-channel-pipette-line.html Tue, 18 Aug 2026 22:10:03 +0530 Eppendorf has introduced a new addition to their Eppendorf Research 3 neo single channel pipette line, launched in 2025: Starting today, laboratories worldwide can order 3-pack and 6-pack bundles offered at a special rate, making it easier and more cost-effective to upgrade to the latest in Eppendorf pipetting technology. Details of the new offering include- 3-pack bundles: Choose from three sets, each tailored to common laboratory needs: o Option 1: 10 µL, 100 µL, and 1000 µL pipettes o Option 2: 20 µL, 200 µL, and 1000 µL pipettes o Option 3: 1000 µL, 5 mL, and 10 mL pipettes 6-pack bundle: Includes 2.5 µL, 10 µL, 20 µL, 100 µL, 200 µL, and 1000 µL pipettes, plus a Pipette Carousel 2 for convenient and safe storage. Bonus item: All multi-packs include an original Eppendorf pipette pen. Research 3 neo pipettes address key pain points for scientists, such as faster and easier volume adjustment with a lock to prevent accidental volume changes during pipetting, improved ergonomics with a shorter pipetting button, flexible labeling options, and the trusted reliability and ergonomics Eppendorf is known for. ]]> https://biospectrumindia.com/features/117/28418/back-to-basics-a-simple-guide-to-checkweighing-in-pharmaceutical-production.html https://biospectrumindia.com/features/117/28418/back-to-basics-a-simple-guide-to-checkweighing-in-pharmaceutical-production.html Tue, 18 Aug 2026 00:00:00 +0530 What Is Checkweighing? Dynamin checkweighing measures individual products as they move along a production line. Unlike a static laboratory balance, a dynamic checkweigher can inspect every item without interrupting production. As a vial, blister pack or carton passes across the weighing platform, its weight is compared with pre-set tolerances. Products that fall outside these limits can then be automatically rejected. This makes checkweighing valuable for more than simply confirming weight. A small difference can indicate an incorrect fill level or a missing leaflet, tablet, syringe, cap or other component. Where is Checkweighing Used? The role of the checkweigher varies depending on the product and where it is positioned on the line. In solid-dose production, systems are commonly used after filling or packaging to check tablet bottles, blister packs, sachets and cartons for completeness. For liquid medicines, checkweighers can monitor the fill level of vials, ampoules, bottles and syringes. Weight data can be fed back to upstream filling equipment, helping manufacturers identify filling drift and make adjustments before it leads to product giveaway or rejected batches. The same principle can be applied to medical devices, including auto injectors and diagnostic kits, where an unexpected weight can indicate a missing component. Supporting Pharmaceutical Compliance Checkweighing is particularly valuable in pharmaceutical production because processes must be controlled, validated and documented. Modern systems can support Good Manufacturing Practice (GMP) guidelines, as well as qualification processes covering Design, Installation, Operational and Performance Qualification. They can also support electronic data integrity requirements aligned with FDA 21 CFR Part 11. Weight and performance data can be transferred into site-level systems, supporting traceability, batch documentation and investigations. Technologies such as FlashCell™ from Mettler Toledo allow high-precision weighing at fast production speeds, while features including locking reject bins, air-pressure monitoring, operator event logs and signalling devices provide additional control around inspection and rejection. Equipment Qualification Packs and Due Diligence Kits from Mettler Toledo can provide further documentation to support validation and demonstrate that systems are operating as intended. More than a Compliance Tool Although regulatory requirements are a major reason for investing in checkweighing, the technology can also deliver wider operational benefits. High-speed weighing and automated rejection can support throughput and reduce manual intervention, while feedback control helps limit product giveaway and improve yield. Recorded weight data also strengthens traceability and can support faster investigations, while modular system designs allow quicker format changeovers for smaller batches or contract manufacturing. For pharmaceutical manufacturers, this combination of precision, efficiency, flexibility and traceability makes dynamic checkweighing an important part of maintaining quality throughout production. ]]> https://biospectrumindia.com/news/117/28321/thermo-fisher-launches-vanquish-amplify-uhplc-system-and-orbitrap-excedion-mass-spectrometer-in-india.html https://biospectrumindia.com/news/117/28321/thermo-fisher-launches-vanquish-amplify-uhplc-system-and-orbitrap-excedion-mass-spectrometer-in-india.html Sat, 15 Aug 2026 14:02:49 +0530 At the recently held Biopharma Summit 2026 in Hyderabad, Thermo Fisher unveiled innovative products for the Indian researchers and scientific community. A highlight of the day was the launch of the Thermo Scientific™ Orbitrap™ Excedion™ mass spectrometer, marking an exciting step forward in next-generation biotherapeutic characterisation. Powered by industry-leading high-resolution accurate-mass (HRAM) technology, the Orbitrap Excedion is designed to help scientists tackle increasingly complex modalities and generate deeper insights, supporting confident decisions across the biopharma development journey. Another highlight was the launch of the Thermo Scientific™ Vanquish™ Amplify UHPLC system, alongside the new Thermo Scientific™ SurePac™ Oligo RP MDi™ and SurePac™ Protein RP MDi™ columns, designed to bring greater confidence and performance to complex biopharma workflows. During an exclusive interaction with selected media, Srinath Venkatesh, Managing Director, India and South Asia, Thermo Fisher Scientific said, “These products have already been launched globally, and now we are bringing them to India in response to customer needs. As the industry moves towards large molecules, there is a great deal of work happening on complex therapeutics, especially oligonucleotides, peptides, proteins, and other complex biologics. The Excedion is specifically designed for those applications.” “Our focus is not just on launching the product, but also on ensuring customers receive the training they need, including data interpretation and data analysis. This summit is about demonstrating how data generated by these instruments is analysed, and we will continue doing that through smaller training sessions with scientists so that we can provide access to all of them”, he further said. Sharing his thoughts on the objective behind organising the Biopharma Summit, Venkatesh said, “This is the second in the series. Last year, we organised what we called the Orbitrap Summit. This year, we have expanded it into the BioPharma Summit. Last year it was held in Bengaluru. This year it is in Hyderabad. Based on how we see it today, this is going to become an annual feature. Tony Acciarito, President, APMEA, Thermo Fisher Scientific said “The feedback from customers last year was very positive. That's why the team believes this is a great forum to continue building on. As we learn more about what works and what doesn't, we will continue to refine and expand it.” The Biopharma Summit 2026 also included a detailed tour of the company’s Customer Experience Centre (CEC), at the Genome Valley in Hyderabad. With a combined investment of Rs 85-90 crore in CEC and the Bioprocess Design Centre (BDC), in Hyderabad’s Genome Valley, Thermo Fisher is building on its investments and growing presence in India. “The Customer Experience Centre and the Bioprocess Design Centre were established in response to what our customers asked for. Our customers and stakeholders clearly told us they wanted access to world-class technology here in India so that researchers could experience it firsthand. They also wanted a partner they could co-create with. Customers also asked us to help solve challenges around productivity and time to market. I think our differentiation lies in responding directly to what our customers are asking us to do. From a talent perspective, we have built partnerships with many of the country's leading academic institutions. Our objective is to integrate all of these into an ecosystem where we can help develop the new talent the industry requires and ensure they acquire these skills”, said Venkatesh. Tony Acciarito further mentioned, “The day we stop listening to our customers and start focusing on being better than our competition is the day we will fail. If our competitors are building similar capabilities, then congratulations to them. More capability on the ground is a positive outcome, regardless of who provides it. For us, the priority is staying very close to our customers.”   Dr Manbeena Chawla (manbeena.chawla@mmactiv.com) ]]> https://biospectrumindia.com/views/117/28251/future-lies-in-integrating-analytical-instrumentation-with-automation-and-intelligent-data-management.html https://biospectrumindia.com/views/117/28251/future-lies-in-integrating-analytical-instrumentation-with-automation-and-intelligent-data-management.html Tue, 04 Aug 2026 12:57:47 +0530 What are the major plans in store for the Indian biotech and pharma market at Anton Paar in 2026? As analytical requirements become more sophisticated, our focus is on strengthening access to world-class analytical, testing and research technologies that support the complete product lifecycle from research and formulation development to quality control and manufacturing. Anton Paar is continuously strengthening its analytical, testing and research portfolio to address the evolving needs of the biotechnology and pharmaceutical industries. As part of this strategy, we have revamped our product portfolio and introduced new analytical product lines across particle characterisation, rheology, density and concentration measurement, viscosity, spectroscopy, microwave sample preparation and advanced material characterization. Alongside these innovations, we are further increasing our investments in application expertise, customer training, laboratory automation and digital workflows to help scientists generate faster, highly reproducible and regulatory-compliant analytical data throughout the product development and manufacturing lifecycle. Our approach is centered on scientific collaboration with pharmaceutical companies, biotechnology firms, research institutes and academia to accelerate innovation through better measurement science. Biotechnology and pharmaceuticals remain among our fastest-growing segments in India. We continue to see strong demand for analytical technologies supporting formulation development, biologics characterisation, particle analysis, rheological testing, sample preparation and quality assurance. With continued investments by Indian pharmaceutical manufacturers in R&D, advanced therapies and globally compliant manufacturing, we expect sustained growth in demand for high-precision analytical instrumentation. Our objective is not only business growth but enabling customers to improve product quality, accelerate development and strengthen regulatory compliance through reliable measurement.   Please share the company's growth plans for strengthening its presence in India. Our strategy is to invest continuously in head count, infrastructure, technology, automation and AI there by strengthening our scientific engagement with customers. We also see significant opportunities in laboratory automation and digitalisation of analytical workflows, helping laboratories improve productivity, data integrity and operational efficiency while maintaining the highest measurement accuracy. We are expanding application expertise, laboratory demonstration capabilities, customer training programmes and nationwide technical support. As analytical workflows become increasingly complex, scientists require more than instruments they need application knowledge, method development support and long-term technical partnership.   According to Anton Paar, what are some of the trends and opportunities facing the Indian biosupplier market? The Indian bio supplier market is witnessing rapid growth, driven by investments in biologics, biosimilars, vaccines, cell and gene therapies, and advanced drug-delivery systems. These areas demand greater analytical precision and deeper material characterisation to ensure product quality, consistency and regulatory compliance. Anton Paar supports this evolution through advanced analytical, testing and research technologies that deliver accurate and reproducible data across R&D, formulation development and quality control. Beyond instrumentation, we work closely with customers on application support, method development and scientific training. An important aspect of our approach is our continuous customer feedback mechanism. We regularly engage with researchers and manufacturers to understand emerging analytical challenges, and these insights are shared with our global R&D teams to drive product enhancements and the development of new solutions that address evolving industry needs.   How can scientific instrumentation support the next wave of biotech and pharma innovation in India, and take it to the global level? Scientific instrumentation is the foundation of pharmaceutical and biotechnology innovation because every scientific breakthrough begins with reliable measurement. Whether researchers are developing biologics, vaccines, biosimilars or advanced drug-delivery systems, they depend on analytical technologies to characterise physical properties, understand formulation behavior and validate product performance. Accurate measurement reduces development time, improves reproducibility and provides confidence in research outcomes. It also enables manufacturers to maintain consistent quality while complying with increasingly stringent global regulatory requirements. As laboratories become more digital, the future lies in integrating analytical instrumentation with automation, intelligent data management and connected laboratory ecosystems that improve productivity without compromising data quality. As India transitions from a global pharmaceutical manufacturing hub to an innovation-driven ecosystem, strengthening its analytical, testing and research infrastructure will be critical. Advanced analytical technologies are essential for developing biologics, precision medicines and complex formulations while ensuring quality, compliance and faster product development. India's Gross Expenditure on Research and Development (GERD) is currently 0.6–0.7% of GDP, compared to the global average of 1.92%, with annual global R&D investments reaching $2.87 trillion. At the same time, India's rise in the Global Innovation Index from 81st in 2015 to 38th in 2025 reflects the country's growing focus on research-led manufacturing. Innovation is equally central to Anton Paar's philosophy, with 14.6% of our global annual turnover invested in R&D. In India, we continue to strengthen our application laboratories, technical expertise, customer training and scientific collaborations to support customers with advanced analytical solutions. We also envision product development that bridges global technology with local application needs. Through continuous customer feedback from Indian laboratories, we collaborate with our global R&D teams to develop application-specific enhancements that address regional materials, manufacturing processes and analytical challenges. As Indian manufacturers increasingly compete in global markets, the distinction between products for domestic consumption and exports is steadily diminishing, making globally benchmarked analytical standards essential across all manufacturing. At Anton Paar, we believe analytical instrumentation is no longer just a laboratory requirement—it is a strategic enabler of innovation, empowering Indian researchers and manufacturers to develop high-quality products that meet both domestic and international standards with confidence.   Dr Manbeena Chawla (manbeena.chawla@mmactiv.com) ]]> https://biospectrumindia.com/views/117/28203/how-ai-multi-omics-and-biologics-are-rewriting-the-future-of-mass-spectrometry.html https://biospectrumindia.com/views/117/28203/how-ai-multi-omics-and-biologics-are-rewriting-the-future-of-mass-spectrometry.html Sat, 01 Aug 2026 11:04:05 +0530 Not long ago, mass spectrometry was regarded as a highly specialised technology found primarily in elite research laboratories and pharmaceutical R&D centres. Today, it is quietly becoming one of the most influential tools shaping modern science. From decoding complex proteins and detecting trace contaminants in food to enabling precision cancer diagnostics and ensuring the quality of biologics, mass spectrometry has moved far beyond the laboratory bench to become a critical enabler of healthcare, biotechnology and industrial innovation. Its role is expanding just as science itself is becoming more data-intensive. When Thermo Fisher Scientific announced its collaboration with OpenAI to integrate artificial intelligence across its scientific instruments and digital ecosystem, it signalled that the future of mass spectrometry would be shaped as much by intelligent software as by advances in hardware. Around the same time, the launch of the FAIR-MS initiative by mzio GmbH, in collaboration with SCIEX, Waters, Agilent and Bruker, marked another watershed moment by enabling artificial intelligence to unlock and compare decades of archived mass spectrometry data across laboratories and instrument platforms. Together, these developments point to a profound shift in analytical science: from simply generating data to transforming it into actionable knowledge. This convergence of scientific innovation, digital transformation and industrial demand is fuelling remarkable market growth. According to Grand View Research estimate, India's mass spectrometry market generated approximately $337.5 million in 2025 and is projected to more than double to $718.5 million by 2033, growing at a CAGR of 9.7 per cent, well above the projected global growth rate. This reflects rising investments in pharmaceutical R&D, biosimilars, clinical diagnostics, food safety, and environmental testing. India is rapidly emerging as one of the industry's most promising growth markets. Backed by a thriving pharmaceutical sector, expanding biosimilar manufacturing, stronger food safety regulations and increasing investments in research infrastructure, the country is steadily building the analytical capabilities needed to support next-generation healthcare and biotechnology. From internationally recognised per- and polyfluoroalkyl substances (PFAS) research at  the Council of Scientific & Industrial Research -Indian Institute of Toxicology Research (CSIR-IITR) in Lucknow and new clinical mass spectrometry facilities at leading hospitals to expanded investments by global technology companies, India is evolving from a fast-growing customer base into an increasingly influential contributor to the future of mass spectrometry. "India is a pivotal market for advanced analytical technologies, with strong demand for mass spectrometry driven by the increasing scale and sophistication of pharma and biopharma innovation," says Nandakumar Kalathil, Country General Manager – India, Agilent Technologies. "As one of the world's leading producers of generic medicines and an increasingly important hub for biologics and biosimilars, India is investing in advanced analytical capabilities to meet innovation needs and global regulatory standards." The Technology Revolution: AI, Miniaturisation, and the Software Turn If the past decade was about increasing the sensitivity and resolution of mass spectrometers, the current era is defined by intelligence, efficiency, and accessibility. Artificial intelligence is no longer a futuristic add-on, it is rapidly becoming integral to instrument design. Shimadzu's latest LCMS-8065XE, showcased at ASMS 2026, features an AI Performance Concierge for predictive maintenance and a Peakintelligence module for automated peak detection, claiming a 67 per cent reduction in manual data review time. SCIEX's new novus V55, also launched at ASMS 2026, ships with SCIEX OS 5.0 software featuring a natural language AI help function and AI-driven Calculated Columns. Thermo Fisher has formalised a strategic collaboration with OpenAI to embed artificial intelligence across its entire product and services ecosystem. In parallel, a cross-vendor initiative is emerging to democratise historical MS data. At ASMS 2026, mzio GmbH announced the launch of FAIR-MS, developed with SCIEX, Waters, Agilent, and Bruker, to apply AI to the reuse and comparative analysis of archived mass spectrometry datasets across instruments and laboratories. It is perhaps the clearest signal yet that the industry is shifting from hardware competition to data ecosystem competition. Miniaturisation and portability are equally transformative. New compact and field-deployable systems are enabling on-site testing in clinical, environmental, and forensic settings without sacrificing analytical rigor. Sustainability, once an afterthought, has become a real procurement criterion: the SCIEX novus V55 offers a 35 per cent smaller footprint and 40 per cent reductions in energy consumption, while Shimadzu's LCMS-8065XE claims 63 per cent lower running costs than competing systems. With laboratories facing constrained budgets, grid capacity limits, and green procurement mandates, this is not merely marketing, it reflects genuine market pressure. On the software side, the segment is expected to grow at the highest CAGR of 9.6 per cent through 2031, as demand for integrated data management, AI-powered spectral analysis, and compliance-ready workflows eclipses growth in hardware alone. Global Instrument Launches: A Wave of Innovation The pace of new product introductions underscores the dynamism of the sector. At ASMS 2025, Thermo Fisher unveiled the Orbitrap Astral Zoom, building on its predecessor with 30 per cent faster scan speeds, 40 per cent higher throughput, and 50 per cent expanded multiplexing capabilities, alongside the Orbitrap Excedion Pro for precision proteoform analysis. Waters launched the Xevo TQ Absolute XR at the same conference, its most sensitive benchtop tandem quadrupole yet, designed for pharmaceutical quantitation and PFAS detection, consuming up to 50 per cent less power and occupying up to 50 per cent less bench space than comparable instruments. By ASMS 2026, Waters raised the bar again with the Xevo MRT P10, a high-resolution QTof system delivering up to 20x higher MS/MS sensitivity and 2x faster acquisition than its predecessor. Bruker's timsOmni platform, launched in 2025, has ushered in a new era for functional proteomics and proteoform sequencing. At ASMS 2026, the company introduced the timsMRMS, combining trapped ion mobility spectrometry with magnetic resonance mass spectrometry, a significant step toward higher-order structural analysis at scale. SCIEX's novus V55 represents the fifth generation of its triple quadrupole lineage, redesigned from the ground up based on direct customer feedback prioritising throughput, footprint, and power efficiency. Agilent's InfinityLab Pro iQ Series rounds out a field of instruments pushing simultaneously toward greater intelligence, smaller size, and lower operational cost. The LC-MS segment continues to dominate the market with a 57.5 per cent share, while ICP-MS is the fastest-growing technology type, driven by surging demand for ultra-trace elemental analysis in pharmaceutical purity testing, heavy metal detection in food safety, and environmental contaminant monitoring. Multi-Omics: The Convergence Reshaping Discovery Underlying much of this instrument-level innovation is a deeper scientific shift: the move from single-technique analysis to integrated, systems-level biology. "Biological systems are regulated through strongly interconnected molecular layers that cannot be accurately resolved using single-omics approaches," says Dr Rajendra Kumar Jadi, Assistant Professor at the School of Pharmacy, Anurag University, Hyderabad. "Mass spectrometry (MS)-based multi-omics integration is recognised as a central analytical strategy by enabling direct, high-resolution measurement of proteins, metabolites, and lipids, thereby supporting systems-level biological interpretation and translational discovery." He points to cancer biology, metabolic disorders, neurodegenerative diseases, and environmental research as areas where this approach has already improved biomarker robustness and mechanistic resolution, and expects continued advances in instrumentation, acquisition strategies, and computational integration to further sharpen biological interpretability. That view is echoed from a clinical vantage point by Akhilesh Pandey, M.D., Ph.D., of the Department of Laboratory Medicine and Pathology at Mayo Clinic, Rochester, USA. He notes, “Mass spectrometry is increasingly becoming a cornerstone of precision medicine as it converges with genomics, proteomics, metabolomics, and other omics technologies.” Pandey points to a 2025 review in the Orphanet Journal of Rare Diseases, which found that integrating these multi-omics approaches offers deeper insight into disease biology, supporting more accurate diagnoses, biomarker discovery, and personalised therapies. “The technology is expanding beyond research into clinical practice itself- into newborn screening, disease diagnostics, and therapeutic monitoring, even as challenges around standardisation and accessibility remain, with high-resolution instruments, LC-MS/MS, and AI-driven data analysis accelerating adoption across healthcare and biomedical research,” he added. A key trend shaping platform design, according to Kalathil, is the growing complexity of the molecules being analysed. "A key trend is the focus on complex biologics and precision medicine, requiring high-sensitivity, accurate-mass technologies for end-to-end molecular characterisation," he says. "This is driving the adoption of advanced MS platforms and application-specific workflows. Increasingly, customers are looking not just for instrumentation, but for complete, validated workflows that can accelerate development timelines while ensuring global compliance." That shift toward integration is reshaping what customers expect from vendors. "At the same time, there is a shift toward integrated, workflow-based solutions, especially among CROs, CDMOs, and fast-scaling pharma companies: to improve productivity and ensure compliance," Kalathil notes. "We are seeing this play out in areas such as biopharma characterisation and impurity profiling, where integrated LC-MS workflows are becoming critical for consistent, reproducible outcomes across labs. We are also seeing the rising adoption of high-throughput systems, automation, and connected digital labs. This convergence of automation and informatics is helping laboratories move toward more predictive and insight-driven operations." India: Regulation, Research, and a Rising Role In India’s mass spectrometry market, the most significant structural change is regulatory. In December 2025, the Food Safety and Standards Authority of India (FSSAI) finalised technical specifications for high-end equipment including GC-MS/MS, LC-MS/MS, and ICP-MS,  standardising instrumentation across the country's National Food Laboratories. This single regulatory action is expected to drive a wave of procurement activity across government labs. Reinforcing this, FSSAI from January 2026 now mandates that food safety reviews be backed by scientific data, including toxicological studies and India-specific consumption evidence, a framework that will require robust analytical infrastructure. On the research front, India's most prominent mass spectrometry story in 2025-26 has come from CSIR-IITR in Lucknow. The institute has been building detection capabilities for PFAS or "forever chemicals", using Waters' advanced LC-MS technologies, with a mandate to generate the nationwide data required for regulatory limits to be set. This work earned the Analytical Science Article of the Year at the 2026 SelectScience Scientists' Choice Awards, presented at ASMS 2026. The recognition placed India's MS research capability on the global stage. On the industry side, global majors are deepening their India commitments. Thermo Fisher Scientific opened a new Bioprocess Design Center in Hyderabad in late 2025 as part of its Asia-wide biopharma infrastructure buildout, adding to an existing footprint of eight manufacturing facilities, five application labs, and two R&D centres across the country. The broader pharmaceutical industry context, India targeting $130 billion in pharma revenues by 2030, with a growing biosimilars pipeline, means demand for advanced analytical instruments is being pulled from both quality control and R&D directions simultaneously. Pharma and biopharma remain the single biggest growth engine, Kalathil says. "The strongest growth is driven by the pharmaceutical and biopharmaceutical sectors, where it plays a critical role across drug development and quality control, particularly for biologics and biosimilars. This aligns with India's leadership in generics and its push toward higher-value therapeutics for global markets. In this space, we are seeing mass spectrometry increasingly embedded as a core platform for both innovation and quality assurance." High-resolution mass spectrometry is also emerging in clinical oncology: India's significant cancer burden is driving interest in High Resolution Mass Spectrometry (HRMS)-based early biomarker detection, and academic hospitals are beginning to integrate MS-based proteomics into translational cancer research workflows. This dovetails with what Kalathil describes as a broader multi-omics wave. "Beyond pharma, multi-omics research is gaining momentum across academic and biotech ecosystems, supporting biomarker discovery and precision medicine," he says. "Here, the focus is shifting toward integrated omics workflows that combine data depth with scalability, an area where advanced MS plays a central role." Applied sectors are catching up quickly too. "Applied markets such as food safety and environmental monitoring are also expanding, driven by stricter regulations and the need for sensitive detection of contaminants like pesticide residues and adulterants," Kalathil says. "Given India's scale and diversity of samples, there is a strong need for robust, high-throughput solutions that can deliver consistent results across varied testing environments. Emerging areas such as biofuels and sustainability research are creating additional demand. Clinical and diagnostic applications are also gaining interest with advances in high-throughput analysis, particularly in specialised and reference lab settings." Across the country, a wave of institutional MS facility installations signals that adoption is moving well beyond the metro research elite. The Government Medical College & Hospital, Chandigarh has commissioned a new LC-MS/MS platform for advanced clinical diagnostics, one of the first such deployments in a government teaching hospital in northern India. Kasturba Medical College, Manipal has set up a triple quadrupole LC-MS/MS facility dedicated to metabolic disease diagnostics, strengthening the analytical foundation for its clinical and translational research programmes. Lucknow University has inaugurated a new HRMS facility, adding to the city's growing reputation as an analytical science hub alongside CSIR-IITR. In the Northeast,  North Eastern Indira Gandhi Regional Institute of Health & Medical Sciences (NEIGRIHMS), Shillong has established a GC-MS forensic toxicology facility, a particularly significant development given the historically limited analytical infrastructure in the region, and one that will support both criminal investigations and clinical poisoning cases across the Northeast. On the industry side, Agilent Technologies has opened a new Biopharma Experience Center in Hyderabad, bringing together its chromatography, mass spectrometry, and laboratory informatics technologies under one roof. The centre is designed to give Indian biopharma and biotech companies hands-on access to Agilent's latest platforms for method development, applications support, and workflow optimisation, a move that reflects Hyderabad's consolidation as India's pharmaceutical and life sciences capital. "At Agilent, we are focused on helping customers generate reliable, regulatory-ready insights and accelerate decision-making aligned with global benchmarks, while working closely with them in India to co-develop solutions that are tailored to local scale, complexity, and regulatory expectations," Kalathil says. Outlook: The Decade of Intelligent Mass Spectrometry The mass spectrometry industry is entering a phase defined less by raw instrument performance and more by workflow integration, data intelligence, and democratisation of access. The competitive frontier is shifting from who makes the most sensitive detector to who builds the most complete analytical ecosystem, one that spans hardware, software, cloud data management, and AI-assisted interpretation. For India, the opportunity is particularly significant. A maturing pharmaceutical sector, a government regulator demanding better analytical infrastructure, world-class research institutions beginning to generate globally recognised data, and a rapidly growing clinical diagnostics market are all converging. What India has lacked in mass spectrometry: scale, standardisation, and policy-backed investment, is now beginning to materialise. As Kalathil puts it, the shift across sectors is toward "connected, insight-driven laboratories rather than standalone testing environments," with the goal, in his words, of "translating these capabilities into real-world impact, from accelerating drug development to strengthening public health and environmental outcomes in India, while helping position Indian labs for greater global competitiveness." The decade ahead may well see India evolve from a market that imports mass spectrometry to one that increasingly defines how it is used.   Mansi Jamsudkar Padvekar  mansi.jamsudkar@mmactiv.com ]]> https://biospectrumindia.com/news/117/28226/sciex-launches-new-solutions-to-help-clinical-labs-move-faster-from-sample-to-answer-.html https://biospectrumindia.com/news/117/28226/sciex-launches-new-solutions-to-help-clinical-labs-move-faster-from-sample-to-answer-.html Tue, 28 Jul 2026 22:30:23 +0530 Sciex, a Danaher company and leader in life science analytical technologies, has announced new solutions designed to help clinical laboratories move from sample to answer faster with greater confidence, productivity and control. The ExionLC MD system and Sciex OS software for the clinical portfolio simplify complex workflows, automate routine processes, and support the delivery of high-quality patient-critical results. Sciex OS software is an intuitive software platform built for maximum impact. Key features include- Enhanced lab productivity with integrated automation, Streamlined workflows for higher throughput, and Compliance-ready data management. The ExionLC MD system delivers high-performance UHPLC separation with the robustness and reproducibility required for clinical workflows, empowering labs to generate consistent, high-quality data with confidence. Designed to work with the Citrine system and the Sciex 4500MD system, it offers a complete LC-MS/MS solution for clinical labs. Key features include Higher-throughput performance, Enhanced analytical sensitivity, Advanced workflow flexibility. ]]> https://biospectrumindia.com/news/117/28188/beckman-coulter-diagnostics-launches-fully-automated-urinalysis-system.html https://biospectrumindia.com/news/117/28188/beckman-coulter-diagnostics-launches-fully-automated-urinalysis-system.html Fri, 24 Jul 2026 13:48:37 +0530 Beckman Coulter Diagnostics, a Danaher company and a global leader in clinical diagnostics, has announced the US launch of the DxU 1800 System, a fully automated urinalysis solution that combines a new chemistry analyser and consumables with proven microscopy technology. The system is designed to help laboratories deliver standardised results at scale, enabling clinicians to move from testing to decision making with confidence. As part of Beckman Coulter Diagnostics' connected ecosystem, the DxU 1800 System combines the new DxU 1800c Chemistry analyser with a DxU Iris Microscopy analyser to deliver a fully automated, integrated urinalysis platform. Together, these technologies unify chemical analysis and particle imaging within a single high throughput system, helping laboratories scale operations with greater consistency and control. The integrated solution streamlines end-to-end urinalysis by reducing manual handoffs and enabling more standardised workflows across chemistry and microscopy. By automating and connecting these processes, the DxU 1800 System leverages the DxU Iris automated urinalysis solution streamlines workflow by reducing manual microscopic review rates to less than 3%, helping laboratories improve throughput, reduce variability, and redeploy staff to higher-value tasks. As a standalone, the DxU 1800c Chemistry analyser can process up to 300 samples per hour, supports expansive result storage of up to 2,000,000 samples and 100,000 strip images, and displays onscreen strip image results for easy review. ]]> https://biospectrumindia.com/news/117/28138/dna-script-expands-access-to-on-demand-dna-synthesis-in-india-through-distributor-agreement-with-imperial-life-sciences.html https://biospectrumindia.com/news/117/28138/dna-script-expands-access-to-on-demand-dna-synthesis-in-india-through-distributor-agreement-with-imperial-life-sciences.html Thu, 16 Jul 2026 17:13:12 +0530 DNA Script, the programmable biology company developing next-generation enzymatic DNA synthesis (EDS) technologies, has announced a new distribution agreement with Gurugram-based Imperial Life Sciences (ILS), expanding access to the company's SYNTAX® platform across India. Under the agreement, ILS will distribute DNA Script's SYNTAX platform throughout the country, providing local sales, technical support and application expertise to researchers seeking faster, more flexible access to high-quality single-stranded DNA (ssDNA) oligonucleotides. The agreement with ILS builds on DNA Script’s recent expansion of its global distribution network across Latin America and East Asia, extending the availability of the SYNTAX platform into another key growth market for life sciences research. The partnership supports the company’s strategy to broaden adoption of decentralized, on-demand DNA synthesis and strengthen access to DNA production capabilities in rapidly growing research ecosystems. By shifting DNA production from centralised manufacturing facilities to the laboratory bench, researchers gain greater control over workflows, faster turnaround times and reduced dependence on complex supply chains. The SYNTAX platform combines DNA synthesis, purification and normalisation in a single automated workflow, allowing laboratories to produce up to 384 oligonucleotides in parallel and accelerate design-build-test cycles across a wide range of research applications.   ]]> https://biospectrumindia.com/news/117/28081/neb-launches-companion-module-for-oxford-nanopore-technologies-direct-rna-sequencing.html https://biospectrumindia.com/news/117/28081/neb-launches-companion-module-for-oxford-nanopore-technologies-direct-rna-sequencing.html Tue, 07 Jul 2026 21:01:04 +0530 New England Biolabs (NEB®) has launched the NEBNext Companion Module for Oxford Nanopore Technologies Direct RNA Sequencing. The companion module contains the NEB reagents recommended by Oxford Nanopore for execution of the Direct RNA Sequencing workflow (RNA004 sequencing kit), providing a simple and convenient format for scientists performing a wide range of applications where direct sequencing of native RNA is critical. The companion module contains the recommended components in volumes compatible with the protocol and are lot-qualified together through preparation and sequencing. Featured is the recommended use of Induro® Reverse Transcriptase, an intron-encoded reverse transcriptase that is used for cDNA synthesis, primarily to reduce RNA secondary structure and improve passage of the RNA molecule through the pore, enhancing sequence yield and quality. Direct RNA sequencing presents new opportunities versus traditional approaches that rely on sequencing the corresponding cDNA, including applications for identifying RNA modifications, tRNA sequencing, and characterization of mRNA for therapeutic purposes. ]]> https://biospectrumindia.com/news/117/28060/sartorius-appoints-avantor-india-for-distribution-of-filter-papers.html https://biospectrumindia.com/news/117/28060/sartorius-appoints-avantor-india-for-distribution-of-filter-papers.html Wed, 01 Jul 2026 22:48:31 +0530 Avantor, a leading global provider of mission-critical products and services to the life sciences and advanced technology industries, has been appointed the exclusive distributor of Sartorius Filter Papers in India. This partnership strengthens Avantor India’s filtration portfolio and enhances access for customers across academic research, quality control, pharmaceutical, biotechnology, food & beverage, and industrial laboratories. Sartorius filter papers are widely recognised for their consistent performance, precise pore structures, and suitability for a broad range of qualitative and quantitative laboratory and industrial filtration applications. Through this partnership, customers can procure Sartorius filter paper through Avantor’s established distribution network, supported by reliable customer service and expert guidance on product handling, storage, and selection across common laboratory environments. The Sartorius filter paper range addresses routine laboratory filtration needs, including sample clarification, gravimetric analysis, environmental testing, and process quality control. With Avantor as the exclusive distributor in India, customers can expect reliable supply, strong product availability, and technical support backed by a global life sciences organisation. ]]> https://biospectrumindia.com/news/117/28010/highres-and-waters-collaborate-to-advance-drug-discovery-through-robotic-automation.html https://biospectrumindia.com/news/117/28010/highres-and-waters-collaborate-to-advance-drug-discovery-through-robotic-automation.html Wed, 24 Jun 2026 12:12:29 +0530 HighRes® has announced a strategic collaboration to enable robotic capabilities on Waters Biosciences, formerly BD Biosciences, flow cytometers to automate key experimental steps and streamline research workflows, from basic research to drug discovery. The companies are integrating the BD FACSLyric™ Flow Cytometer with the HighRes Nucleus® Automation and Cellario® Software Platforms, enabling scientists to utilise robotic arm capabilities to run reliable, complex, multi-step experiments unattended with continuous operation of up to three times more experimental runs per day. The integration enables higher-throughput studies, improves reproducibility, and allows for greater operational efficiency. "The BD FACSLyric™ Flow Cytometer, when paired with HighRes automation, is an ideal solution for laboratories running complex flow cytometry studies that demand scale and precision, including for higher volumes of experiments," said Eric Diebold, Vice President and General Manager, Instruments & informatics, Waters Biosciences, Waters Corporation. "This collaboration exemplifies our long-term commitment to advancing robotic automation across our complete portfolio of flow cytometers, unlocking a new dimension of automation for research and biopharma partners aiming to bring their potentially life-changing therapies to market even faster.” “With this collaboration, scientists can run more experiments per day with consistent quality, reduce hands-on time from hours to minutes, and design assays that were previously too complex or time-sensitive to automate – with every step tracked for complete data integrity and reproducibility,” said Ira Hoffman, CEO, HighRes. “By combining BD’s expertise in flow cytometry and HighRes’ leadership in lab automation, we are enabling more labs around the world to operate with true end-to-end confidence.” ]]> https://biospectrumindia.com/news/117/27924/waters-launches-industry-first-reversed-phase-bioseparation-columns.html https://biospectrumindia.com/news/117/27924/waters-launches-industry-first-reversed-phase-bioseparation-columns.html Tue, 09 Jun 2026 16:47:14 +0530 US-based Waters Corporation has announced the launch of the BioResolve™ Peptide and GTxResolve™ Lipid Phenyl-Hexyl+ and C18+ Columns, a first-of-its-kind reversed-phase (RP) column platform designed to tackle a persistent biopharmaceutical challenge: reliably separating structurally and chemically similar impurities in GLP-1 peptides, insulin, and lipid nanoparticles (LNPs) to support the development of safe, effective drug products. In GLP-1 receptor agonists and newer mRNA-based therapies such as in vivo CAR T, difficulty resolving impurities can delay time to market, weaken regulatory confidence, and affect patient safety. Traditional RP columns do not always separate low-level or closely related impurities well, often requiring longer analyses, detector-suppressing mobile-phase additives, or repeated method redevelopment. BioResolve Peptide and GTxResolve Lipid Columns help to overcome these limitations with ready-to-use methods that improve both resolution and speed while fitting into existing workflows. BioResolve Peptide and GTxResolve Lipid Columns use specially designed surface chemistries and superficially porous particles to deliver precise RP separations with selectivity for two difficult sample types. Available in Phenyl-Hexyl+ and C18+ chemistries with 230 Å pore size particles, they are designed to support efficient mass transfer, consistent performance across U(H)PLC and HPLC systems, and reliable, batch-tested results from early-stage research through manufacturing. Waters' BioResolve Peptide and GTxResolve Lipid Columns will be available globally beginning June 9, 2026, starting with the 1.6 µm Phenyl-Hexyl+ phase.  ]]> https://biospectrumindia.com/news/117/27899/waters-unveils-xevo-mrt-p10-mass-spectrometer-for-high-throughput-multiomics.html https://biospectrumindia.com/news/117/27899/waters-unveils-xevo-mrt-p10-mass-spectrometer-for-high-throughput-multiomics.html Tue, 02 Jun 2026 18:51:36 +0530 US-based Waters Corporation has introduced the Waters Xevo™ MRT P10 Mass Spectrometer (MS), a high-resolution Quadrupole Time-of-Flight (QToF) System for high-throughput multiomics, bioanalysis, and biopharmaceutical laboratories. The Xevo MRT P10 MS delivers up to 20x higher MS/MS sensitivity compared to its predecessor, along with industry-leading speed and expanded acquisition modes to comprehensively support both targeted and untargeted analysis in a single benchtop platform. The system is designed to accelerate biomarker discovery and validation while supporting the identification of disease pathways and therapeutic targets across large-cohort biomedical research and epidemiology studies. As researchers pursue deeper analytical insights, they face a bottleneck: generating high quality MS/MS information at the speed required by modern workflows. The Xevo MRT P10 MS is engineered to solve that problem. It offers up to 20× greater MS/MS sensitivity, helping scientists detect low-abundance compounds in complex samples.  With acquisition speeds twice as fast as its predecessor, it is the fastest benchtop HRMS system currently available. The new system supports rapid throughput, alongside exceptional resolution and mass accuracy, delivering the highest data quality and confidence. When combined with the DESI XS ion source, rapid spatial analysis is unlocked down to the cellular level at up to 200 Hz, increasing throughput six-fold while preserving image quality. The Xevo MRT P10 MS is perfectly positioned to support long-term growth across multiomics, including proteomics, lipidomics, and metabolomics, as well as biopharmaceutical analysis and drug discovery.  ]]> https://biospectrumindia.com/news/117/27886/agilent-launches-new-gc-systems-to-improve-laboratory-efficiency-and-data-quality.html https://biospectrumindia.com/news/117/27886/agilent-launches-new-gc-systems-to-improve-laboratory-efficiency-and-data-quality.html Mon, 01 Jun 2026 16:46:49 +0530 Agilent Technologies Inc. has announced the launch of the new 8890B GC and 8860B GC with GC Assist. GC Assist is the new, advanced instrument intelligence that provides system monitoring, built-in troubleshooting, and remote connectivity to analytical instrumentation within the laboratory’s secure network. These systems enable higher performance and productivity across gas chromatography (GC) analyses.The new systems are designed to help laboratories reduce unplanned downtime, improve data quality, and operate more efficiently by combining updated GC hardware with integrated system monitoring, diagnostics, step-by-step troubleshooting, and maintenance procedures through GC Assist.  The 8890B and 8860B extend GC system capabilities with enhancements designed to support higher throughput, flexibility, and ease of use. An oven light improves visibility during maintenance, while onboard maintenance videos help new users complete routine procedures. The 8860B GC increases throughput with dual simultaneous injections, while the 8890B adds flexibility with an additional detector position, supporting up to four detectors in valve configurations. The 8890B also offers up to a 30% faster oven cooling rate compared to previous models, reducing injection-to-injection cycle times and enabling laboratories to increase daily sample throughput without changing established method parameters. The new systems are being introduced globally and will be supported through Agilent’s worldwide sales, service, and application teams.  ]]> https://biospectrumindia.com/news/117/27851/tecan-establishes-direct-sales-and-specialist-lab-automation-service-operations-in-india.html https://biospectrumindia.com/news/117/27851/tecan-establishes-direct-sales-and-specialist-lab-automation-service-operations-in-india.html Tue, 26 May 2026 16:13:42 +0530 Swiss firm Tecan, a global provider of laboratory automation and solutions, has announced the launch of direct operations in India, including a dedicated local sales and service team based in Gurugram, near New Delhi. The launch, marked with a ribbon-cutting ceremony, is an important milestone in the company’s geographical expansion and reinforces its commitment to serving customers in one of the world’s most dynamic and fastest-growing life sciences markets. For over a decade, Tecan has supported customers in India through its trusted distributor partner Bioscreen. As it establishes a direct presence, Tecan will continue to work with Bioscreen, combining local expertise with closer customer engagement and strengthened support. The establishment of Tecan India, incorporated on April 1, 2026, brings the company closer to customers across the pharmaceutical, biotechnology, academic and diagnostic sectors, enabling more direct collaboration and responsive local support. Mukta Acharya, EVP and Head of Tecan’s Life Sciences business, said: “India is a key market for the future of life sciences, with strong momentum across CROs, pharma, biotech and diagnostics. Establishing a direct presence allows us to be closer to our customers, deepen collaboration and further strengthen the value we deliver locally.” Building on its expansion into South Korea in 2024, Tecan is strengthening its presence in high-growth regions as part of its ongoing commitment to improving the lives and health of people. It does this by enabling its customers to scale healthcare innovation globally. ]]> https://biospectrumindia.com/news/117/27680/thermo-fisher-scientific-launches-applied-biosystems-powerflex-thermal-cycler.html https://biospectrumindia.com/news/117/27680/thermo-fisher-scientific-launches-applied-biosystems-powerflex-thermal-cycler.html Sat, 18 Apr 2026 00:00:00 +0530 Thermo Fisher Scientific Inc., the world leader in serving science, has announced the Applied Biosystems™ PowerFlex™ Thermal Cycler, a next-generation polymerase chain reaction (PCR) instrument designed to help deliver enhanced flexibility, precise thermal performance and improved productivity for modern molecular biology laboratories. Building on the trusted legacy of Applied Biosystems™ instruments, this solution is designed to help laboratories run complex PCR workflows with greater confidence and efficiency. PCR remains a foundational technique across life science research, applied testing and DNA identification. As labs face increasing pressure to generate accurate results faster — often while sharing instruments across teams — there is growing demand for thermal cyclers that combine performance, adaptability and ease of use in a reliable platform. Featuring the latest block technology, the PowerFlex Thermal Cycler was developed to help address these evolving needs. With advanced thermal technology engineered for speed and precision, the system helps laboratories shorten run times while maintaining the accuracy and reproducibility researchers depend on. Its optimised performance supports confidence across routine and complex PCR workflows alike. The PowerFlex Thermal Cycler is intended for use across a wide range of applications, including life science research, large academic and core laboratories, biotechnology and pharmaceutical research, food and environmental testing and human identification workflows. ]]> https://biospectrumindia.com/news/117/27674/waters-announces-ce-mark-for-next-generation-fully-automated-bd-bactec-fxi-culture-system.html https://biospectrumindia.com/news/117/27674/waters-announces-ce-mark-for-next-generation-fully-automated-bd-bactec-fxi-culture-system.html Fri, 17 Apr 2026 00:00:00 +0530 US-based Waters Corporation has announced that the BD BACTEC™ FXI Culture System has received CE marking under the European Union's In Vitro Diagnostic Regulation (IVDR), enabling commercialisation in Europe and representing a key milestone in the Company's clinical microbiology portfolio expansion. The BD BACTEC FXI System is a next-generation, fully automated blood culture system designed to improve the speed, consistency, and accuracy of bloodstream infection diagnostics in modern microbiology laboratories. Clinical study data show that the BD BACTEC FXI System delivers a mean time to detection approximately three hours faster (~15% reduction) than the previous generation BD BACTEC™ FX System, supporting earlier detection of pathogens and more timely initiation of targeted antimicrobial therapy in patients with suspected bloodstream infections and sepsis. In 2021, sepsis-related deaths represented 31.5% of total global deaths, with studies showing that each hour of delay in antibiotic administration is associated with increased odds of mortality. A key innovation of the BD BACTEC FXI System is its automated gravimetric measurement of individual blood culture vial volume, the first-of-its-kind capability in a blood culture platform. Studies indicate up to 85% of blood culture vials are inappropriately filled in routine clinical practice, negatively impacting diagnostic accuracy. By objectively confirming blood volume in each vial, the system addresses a well-established source of pre-analytical variability and supports improved diagnostic consistency and adherence to recommended collection practices. The BD BACTEC FXI System is designed for modern, high-throughput microbiology laboratories, featuring fully automated workflows including vial loading, unloading, incubation, and detection alerts. ]]> https://biospectrumindia.com/news/117/27578/eurofins-viracor-launches-expect-anti-cd19-obe-cel-car-t-cell-assay-.html https://biospectrumindia.com/news/117/27578/eurofins-viracor-launches-expect-anti-cd19-obe-cel-car-t-cell-assay-.html Fri, 27 Mar 2026 00:00:00 +0530 Eurofins Viracor, a leader in advanced clinical diagnostics, has announced the launch of the ExPeCT™ anti-CD19 (obe-cel) CAR T-cell assay, a cutting-edge solution designed to help clinicians monitor CAR T-cell therapy performance with validated precision and a quick turn-around-time for results. The ExPeCT™ brand of CAR T-cell assays enables clinicians to monitor CAR T-cell expansion and persistence in real time. This non-invasive blood test delivers results in approximately 24 hours after specimen receipt, potentially helping clinicians make timely therapy decisions. The assay was developed exclusively to test the expansion and persistence of obecabtagene autoleucel (obe-cel) CAR T-cell's - a second-generation CAR T-cell therapy. Eurofins Viracor is a subsidiary of Eurofins Scientific (EUFI.PA), a global leader in bio-analytical testing, and one of the world leaders in genomic services. ]]> https://biospectrumindia.com/news/117/27529/eppendorf-introduces-spinpro-centrifuge-series-to-streamline-life-science-research-.html https://biospectrumindia.com/news/117/27529/eppendorf-introduces-spinpro-centrifuge-series-to-streamline-life-science-research-.html Sat, 21 Mar 2026 00:00:00 +0530 Eppendorf, a leading international life science company that develops, manufactures, and distributes instruments, consumables, and services for use in laboratories around the world, has announced the commercial launch of the SpinPro® 6 R centrifuge, the first in the company’s new range of SpinPro floor-standing and benchtop centrifuges. With an advanced user-interface and ergonomic operation, the SpinPro 6 R provides a flexible, and scalable solution for sample separation. Building on Eppendorf’s established range of benchtop centrifuges, the refrigerated SpinPro 6 R benchtop centrifuge offers additional smart features to streamline workflows including new rotors with universal adapters. These rotors can be interchanged within various models of the upcoming SpinPro line, reducing inventory and minimising costs. With a wide range of compatible vessels, the rotors can support applications such as cell culture harvesting, processing of biological samples and isolation of proteins across pharma, biotech, food, and agriculture sectors. Radio Frequency Identification (RFID) chipped rotors enable instant recognition, increasing safety for both samples and users. All new fixed-angle rotors are equipped with Eppendorf QuickLock® Pro lids for fast and easy one-handed operation. Designed with ergonomics in mind, the SpinPro 6 R is simple to use and easily integrated into existing workflows. Its intuitive software and adaptive 7-inch touch-based display ensure straight-forward set up, while the one-touch operation electric lid drive allows for ergonomic interaction with the device. The SpinPro 6 R is ACT 2.0 labelled, using CO2–based cooling technology without F-gases and full transparency on consumption, production, and sourcing, to contribute to laboratory environmental targets. ]]> https://biospectrumindia.com/news/117/27432/new-england-biolabs-opens-subsidiary-in-bengaluru.html https://biospectrumindia.com/news/117/27432/new-england-biolabs-opens-subsidiary-in-bengaluru.html Fri, 06 Mar 2026 00:00:00 +0530 US-based New England Biolabs (NEB), a world leader in the production of reagents for the life science industry, is extending its global subsidiary network with the opening of New England Biolabs India Pvt Ltd (NEB India) at Phoenix Asia Towers in Bengaluru, Karnataka. India has long been a global leader in the life science space as a result of both strong public sector support and private sector investments. NEB has supported researchers in India for many years through its distribution network.  NEB India will now bring a higher level of service to valued customers and local distributors in this important market. “This new subsidiary office will provide the scientific research community in India with more efficient access to the latest NEB products and technical support in the local time zone, a state-of-the-art Experience Center and footprint for local manufacturing activities, as well as custom partnership opportunities,” says Partha Chakraborty, Country Manager for NEB India. Carole Keating, Executive Director of International Business at NEB said, “This expansion of our subsidiary network in India enables NEB to offer even greater personalized service to our customers, rapid delivery, and the ability to explore higher levels of collaboration.” NEB also maintains subsidiary offices in Australia, Canada, China, France, Germany, Japan, New Zealand, Singapore, South Korea and the United Kingdom.                 ]]> https://biospectrumindia.com/news/117/27426/thermo-fisher-launches-chromogenic-culture-media-to-help-detect-candida-infections-faster.html https://biospectrumindia.com/news/117/27426/thermo-fisher-launches-chromogenic-culture-media-to-help-detect-candida-infections-faster.html Wed, 04 Mar 2026 00:00:00 +0530 Thermo Fisher Scientific has announced the launch of Thermo Scientific™ Brilliance™ Candida 2 Agar and Spectra™ Candida Agar, new colour-based (chromogenic) culture media to help laboratories quickly detect and differentiate clinically important Candida species, including Candida auris, a growing global antimicrobial resistance (AMR) threat. Invasive fungal infections are an increasing challenge for healthcare systems worldwide, driven in part by the rapid spread of Candida auris. This pathogen is often resistant to multiple antifungal treatments, can spread quickly in healthcare settings and is associated with serious illness and high mortality rates. As screening and surveillance efforts expand, clinical microbiology laboratories need faster, reliable tools to identify infections and support infection prevention and control. Thermo Scientific Brilliance Candida 2 Agar and Spectra Candida Agar are designed to address this need by enabling clear, species-specific chromogenic reactions directly from primary culture. This allows laboratories to visually differentiate the most clinically relevant Candida species, including direct identification of Candida auris, with shorter incubation times compared to conventional culture methods. Earlier intervention can support timely clinical decisions, appropriate antifungal therapy, and rapid infection control measures during routine screening and outbreak investigations. ]]> https://biospectrumindia.com/news/117/27113/bd-biosciences-and-csir-igib-inaugurate-its-first-centre-of-excellence-for-single-cell-multiomics.html https://biospectrumindia.com/news/117/27113/bd-biosciences-and-csir-igib-inaugurate-its-first-centre-of-excellence-for-single-cell-multiomics.html Tue, 23 Dec 2025 00:00:00 +0530 BD Life Sciences–Biosciences, a segment of BD (Becton, Dickinson and Company), a global leader in life sciences, in collaboration with Delhi-based Institute of Genomics and Integrative Biology (IGIB), has announced the inauguration of its Centre of Excellence (CoE) for Single-Cell Multiomics in India. The CoE aims to revolutionise single-cell multi-omics research, combining BD’s Rhapsody™ Single Cell Analysis Solutions with CSIR-Institute of Genomics and Integrative (IGIB)'s expertise in high-throughput Next Generation Sequencing (NGS) and Bioinformatics. Commenting on the launch, Atul Grover, Managing Director, BD India/South Asia said, “This Single-Cell Multiomics Centre of Excellence reflects our commitment to empowering scientists with advanced tools that drive innovation in health research. By enabling deeper insights into how cells function, we aim to accelerate discoveries in areas like immunity and cancer. The centre will serve as a hub for training, application support, and collaboration—helping researchers turn complex challenges into real-world solutions, aligned with our purpose of advancing the world of health." Dr Souvik Maiti, Director of CSIR-Institute of Genomics and Integrative Biology (IGIB) added, “CSIR-Institute of Genomics & Integrative Biology (IGIB) is a premier Biology Institute of Council of Scientific and Industrial Research (CSIR), engaged in research of national importance in the areas of Genomics, Molecular medicine, Bioinformatics and Proteomics. Partnering with BD allows us to create a collaborative platform that strengthen India’s research capabilities in Single Cell Multiomics and foster innovation for precision medicine.” In addition to this CoE, BD Biosciences also has CoEs as mentioned below: BD-NCBS CoE in Advanced Flow Cytometry – Bengaluru BD-CMC Vellore CoE in Clinical Flow Cytometry BD-JH FACS Academy BD-Sehgal Path Lab CoE – Mumbai     ]]> https://biospectrumindia.com/news/117/26923/medispec-and-mabtech-announce-exclusive-partnership-to-bring-eyra-multiplexing-platform-to-india.html https://biospectrumindia.com/news/117/26923/medispec-and-mabtech-announce-exclusive-partnership-to-bring-eyra-multiplexing-platform-to-india.html Wed, 12 Nov 2025 00:00:00 +0530 Medispec India Limited, one of India’s leading channel partners of life science and research instrumentation, has partnered with Swedish biotechnology company Mabtech AB for the exclusive distribution of the EYRA multiplexing platform and EYRAplex kits in India. This strategic partnership marks a major step toward expanding access to advanced multiplex immunoassay technologies across India’s academic and biopharmaceutical research communities. Mabtech’s EYRA platform represents a new generation of multiplexing technology designed for high sensitivity, reproducibility, and ease of use in quantitative cytokine analysis. Together with EYRAplex kits, it enables researchers to generate robust, high-quality immunoassay data across multiple analytes from minimal sample volumes — accelerating research in immunology, vaccine development, and cell-based studies. “Medispec’s scientific expertise, technical support capability, and nationwide reach make them the ideal partner for EYRA in India; together we’re leveraging their on-the-ground strength to accelerate adoption and deliver outstanding customer experience to more labs across India. EYRA and EYRAplex provide high-quality results faster than competing technologies and with a remarkably user-friendly workflow. We are essentially distilling 40 years of Mabtech’s antibody and immunoassay development into a reliable, ready-to-run solution which we are confident will help accelerate immunology research in India", said Carles Solà, Head of Sales, EMEA & APAC, Mabtech AB With over three decades of experience representing globally respected scientific instrument manufacturers, Medispec brings deep market expertise, technical excellence, and a strong nationwide service network. The company continues to strengthen its portfolio by introducing transformative technologies that empower Indian researchers and enhance scientific productivity. Vikkalp Chhatbar, Director at Medispec, added, “The EYRA platform represents a new benchmark in multiplex immunoassays — combining simplicity, precision, and scalability. We’re excited to introduce Mabtech’s innovation to Indian researchers and help accelerate breakthroughs in immunology and translational science.” ]]> https://biospectrumindia.com/news/117/26603/thermo-fisher-introduces-next-generation-expression-system-to-expand-protein-research.html https://biospectrumindia.com/news/117/26603/thermo-fisher-introduces-next-generation-expression-system-to-expand-protein-research.html Tue, 26 Aug 2025 00:00:00 +0530 Thermo Fisher Scientific has introduced the Gibco™ Expi293™ PRO Expression System, a next-generation HEK293 transient expression system designed to deliver exceptional protein yields for a wider variety of proteins, including low-yield and challenging proteins, with higher throughput and speed.  HEK293 cells are the most commonly used mammalian cell host for protein expression. They are utilised in a variety of research applications, including drug discovery, structural biology, recombinant vaccines, and cell and gene therapies. For researchers working in these fields, producing increasingly complex proteins with higher yields and higher throughput is critical to accelerating breakthroughs in protein research and therapeutic drug development. The Expi293 PRO Expression System offers exceptional yields, speeds and efficiencies for a wide range of proteins, enabling the expression of proteins that were previously unable to be expressed.   The Expi293 PRO Expression System is composed of a new, clonally derived HEK293 cell line, Gibco Expi293 PRO Cells, which can produce difficult-to-express proteins and support protein production on a milliliter to multi-liter scale. Additionally, the system includes Gibco Expi293 Medium, an optimized culture medium, and Gibco Expi293 PRO Transfection Kit, which enables high-density cell transfection. It also includes components and protocols designed for easy incorporation into automated workflows and a streamlined protocol to minimize hands-on time and maximise the number of transfections that can be performed per week.     ]]> https://biospectrumindia.com/news/117/26574/how-to-choose-the-right-laboratory-vial-for-your-experiment.html https://biospectrumindia.com/news/117/26574/how-to-choose-the-right-laboratory-vial-for-your-experiment.html Fri, 22 Aug 2025 00:00:00 +0530 This guide explains the different types of laboratory vials, their applications in analytical chemistry, and how to select the best option based on sample type, instrument compatibility, and closure type.   Everything You Need to Know about Laboratory Vials   Laboratory vials serve as sample containers in various analytical processes, playing a crucial role in preserving chemical composition, preventing contamination, and maintaining analytical accuracy. Some of the most common functions of laboratory vials are as follows:   Key Functions of Laboratory Vials   Chemical Stability: Ensures compatibility with solvents, acids, and bases used in analytical methods. Sealing Integrity: Prevents evaporation, contamination, or leakage during storage and analysis. Instrument Compatibility: Designed to fit autosamplers for HPLC and GC applications. Regulatory Compliance: Must meet ISO 15378 certification standards for pharmaceutical and chemical testing.   Types of Laboratory Vials Based on Applications   Vial Type Application Sealing Type Typical Volume HPLC Vials Chromatographic analysis (HPLC) Screw Cap / Crimp Top 1.5mL - 2mL GC Vials Gas Chromatography (GC) Crimp Top 1.5mL - 2mL Treated / pH Sensitive Vials For reactive or pH-sensitive samples Screw Cap / Crimp Top 1 mL - 100 mL Certified Vials USP-compliant pharma testing Screw Cap / Crimp 5mL - 50mL   Comparing Screw Cap Vials vs Crimp Top Vials   Screw cap vials from Borosil Scientific and crimp top vials are the most common choices for analytical testing. Selecting between them depends on sealing requirements, handling convenience, and sample volatility.   Feature Screw Cap Vials Crimp Top Vials Snap Top Vials Sealing Strength Moderate (reusable) High (airtight, tamper-proof) Medium to High (Depends on top type) Ease of Handling Can be opened and resealed Requires a crimping tool Easy to open and close Evaporation Resistance Suitable for low-volatility samples Ideal for volatile solvents Suitable for short term storage Instrument Compatibility HPLC and GC autosamplers GC applications requiring airtight sealing HPLC autosamplers with snap top support   Best for HPLC applications: Screw cap vials with PTFE-lined closures. Best for GC applications: Crimp top vials to prevent solvent loss. Best for quick HPLC runs or routine sampling: Snap top vials for fast, manual access.   Material Considerations: Glass vs. Plastic Vials   Material selection impacts sample stability, chemical reactivity, and analytical precision.   Material Properties Applications Borosilicate Glass (3.3 Expansion) High thermal resistance, low alkali content Suitable for high-temperature applications and lab glassware. Borosilicate Glass (4.9 Expansion) Enhanced chemical durability, lower thermal expansion Pharmaceutical packaging, sensitive formulations. Borosilicate Glass (5.1 Expansion) USP Type I compliance, low extractables, chemically inert HPLC, GC, pharmaceutical analysis Amber Glass UV-resistant, prevents light degradation Light-sensitive compounds   For volatile solvents: Choose borosilicate glass for low leachability and chemical stability. For light-sensitive samples: Use amber glass vials to protect against UV exposure.   Certified Sampling & Storage Vials: Ensuring Compliance   For pharmaceutical, chemical, and biological testing, certified vials from Borosil Scientific meet regulatory standards to ensure accuracy and reproducibility.   Key Features of Certified Vials:   ISO “Class 8” Cleanroom Packing: Minimises particulate contamination. USP Type I Borosilicate Glass: Ensures low leachability and chemical purity. PTFE-Silicon Septa Caps: Provide airtight sealing for long-term sample stability. Amber Colour Protection: Shields light-sensitive compounds from degradation.   Certified vials are ideal for pharmaceutical working standards, chemical reference samples, and stability studies.   Selecting the Right Vial for HPLC and GC Analysis   HPLC Vials to Maintain Sample Integrity and Autosampler Compatibility Must be made from low-extractable borosilicate glass. Volume range: 1.5mL - 2mL. Screw cap vials with PTFE/Silicone septa for minimal sample contamination.   GC Vials for Evaporation Control and Precision Sealing Designed for gas chromatography and mass spectrometry (GC-MS). Crimp top vials are preferred for airtight sealing of volatile samples. Septa should be thermally stable for high-temperature GC analysis.   Best Practices for Handling and Storing Laboratory Vials   To maintain vial integrity and prevent contamination, follow these guidelines:   Storage and Handling Store in a clean, dust-free environment. Use vial racks to prevent breakage or misplacement.   Cleaning and Preparation Rinse new vials with HPLC-grade solvents before use. Avoid direct handling. Use tweezers or vial holders.   Sample Management Do not overfill vials. Maintain 20% headspace. Secure caps properly to prevent leakage or evaporation.   Key Considerations for Choosing the Right Laboratory Vial   Factor Why It Matters Chemical Compatibility Prevents leaching, degradation, and contamination Sealing Type Ensures airtight protection for sensitive samples Autosampler Fit Prevents misalignment and cross-contamination Regulatory Compliance ISO 15378-certified vials for pharmaceutical use   For trace analysis: Use low-extractable glass vials to avoid contamination. For long-term sample storage: Choose PTFE-lined screw caps to prevent moisture intrusion.   Conclusion   Selecting the correct laboratory vial from brands like Borosil Scientific is essential for sample integrity, analytical precision, and regulatory compliance. Whether used in HPLC, GC, or chemical storage, vials must be chosen based on material compatibility, sealing strength, and instrument specifications.   For HPLC applications: Use screw cap and snap cap vials with PTFE/Silicone septa. For GC analysis: Opt for crimp top vials to prevent solvent loss. For pharmaceutical storage: Use ISO 15378-certified borosilicate glass vials.   By selecting the right vial for chromatography, sample storage, or reagent preparation, laboratories ensure reliable data, contamination-free workflows, and accurate analytical outcomes. ]]> https://biospectrumindia.com/news/117/26542/brand-gmbh-co-kg-announces-launch-of-new-pipette-in-india.html https://biospectrumindia.com/news/117/26542/brand-gmbh-co-kg-announces-launch-of-new-pipette-in-india.html Mon, 18 Aug 2025 00:00:00 +0530 Germany-based BRAND GMBH + CO KG has announced the latest addition to the Transferpette® S lineup – The new high-performance Transferpette® pro manual pipette. This innovative micropipette builds on the proven user-friendly design of the Transferpette® S with one-handed operation, volume-change protection, and ergonomic design, while introducing exciting new features for enhanced flexibility and customisation to meet individual user needs. The Transferpette® pro's slim design and individually adjustable finger rest adapt perfectly to different hand sizes and pipetting positions. This ensures ergonomic and comfortable operation, even during extended pipetting sessions. Like the Transferpette® S, the Transferpette® pro features Easy Calibration technology for permanent adjustment without tools. What's new is the User Adjustment feature for quick, reversible adaptation to changing conditions. This comes in handy when dealing with challenging fluid properties (such as density, viscosity, vapor pressure), temperature differences between liquid and environment, or special pipette tips. With User Adjustment, you can quickly and safely reset to factory settings at any time. Premium materials and the integrated counter protection make the Transferpette® pro robust and durable. The Transferpette® pro is fully autoclavable (121°C) and available as single-channel, eight-channel, and twelve-channel pipette. Compared to the Transferpette® S, it offers additional volume ranges, such as 50 – 1250 μl for multichannel devices. The new pipettes are available for sale in India from September 2025. ]]> https://biospectrumindia.com/news/117/26501/eppendorf-unveils-next-generation-pipettes-in-india-for-better-accuracy-and-precision.html https://biospectrumindia.com/news/117/26501/eppendorf-unveils-next-generation-pipettes-in-india-for-better-accuracy-and-precision.html Fri, 08 Aug 2025 00:00:00 +0530 Eppendorf has announced the worldwide sales start of its next generation of mechanical pipettes, the Eppendorf Research® 3 neo. The new pipettes offer renowned Eppendorf accuracy and precision, faster or easier volume selection, optimized ergonomics with a shorter pipetting button, and adaptable settings and accessories to customise the pipetting experience for speed, comfort, or accuracy in different applications. The new pipettes are available for sale in India since August 5, 2025. The Research 3 neo pipette is highly adaptable, allowing users to easily speed up or fine-tune volume changes by switching between two volume setting speeds. Users can also temporarily adjust the pipette to accommodate different liquid types, tip geometries, reverse pipetting, and altitudes, ensuring optimal accuracy across various applications without the need for recalibration. Additionally, the new ColorTag changeable pipette marking rings enable users to reversibly label the instrument. Further adding to its customisation options, the Research 3 neo boasts carefully designed ergonomics. Features include a new operating concept with a shorter pipetting button, an ergonomic finger hook, and a well- balanced, lightweight design. Additionally, it offers low tip attachment and ejection forces, ensuring comfortable and efficient use. ]]> https://biospectrumindia.com/news/117/26482/agilent-expands-dako-omnis-family-with-three-new-models-to-meet-evolving-pathology-lab-needs.html https://biospectrumindia.com/news/117/26482/agilent-expands-dako-omnis-family-with-three-new-models-to-meet-evolving-pathology-lab-needs.html Tue, 05 Aug 2025 00:00:00 +0530 Agilent Technologies Inc. has announced the introduction of its Dako Omnis family of instruments with three new models- Agilent Dako Omnis 110, 165, and 165 Duo- designed to meet the evolving needs of pathology laboratories of all sizes. These new instruments provide labs with the flexibility to tailor their staining solutions according to volume, workflow, and diagnostic requirements. With the launch of the Agilent Dako Omnis family, Agilent transitions beyond a one-size-fits-all model to offer a tailored portfolio, empowering labs to select the configuration that best meets their needs. Scalable Solutions for Every Lab—From Routine to Revolutionary. Dako Omnis 110: Built for precision in low-medium volume labs, delivering up to 110 IHC slides per day with dependable performance. Dako Omnis 165: Engineered for efficiency in medium-high volume labs, delivering up to 165 IHC slides per day with seamless consistency. Dako Omnis 165 Duo: Designed for ultimate flexibility in medium-high volume labs, delivering simultaneous IHC and ISH with maximum throughput and confidence. Building on the success of the original Dako Omnis, all models feature continuous, case-based processing and shared reagents, enabling labs to streamline workflows and reduce turnaround times. A newly integrated direct connection for de-ionised water and non-hazardous waste further reduces handling time. ]]> https://biospectrumindia.com/news/117/26428/thermo-fisher-announces-launch-of-scios-3-and-talos-12-electron-microscopes.html https://biospectrumindia.com/news/117/26428/thermo-fisher-announces-launch-of-scios-3-and-talos-12-electron-microscopes.html Thu, 24 Jul 2025 00:00:00 +0530 Thermo Fisher Scientific has announced the launch of two new electron microscopes that will be unveiled at Microscopy & Microanalysis (M&M) in Salt Lake City, Utah, July 27-31, each significantly contributing to the democratisation of research in the sciences. The Thermo Scientific Scios 3 is a focused ion beam (FIB) scanning electron microscope (SEM) with automation to dramatically improve site-specific quality control. The Scios 3 FIB-SEM offers increased productivity for both industry and academia with enhanced lamella preparation, due to advances in FIB column performance. Ease-of-use upgrades will benefit microscopists of all experience levels. On the other hand, Talos 12 adapts to researchers across disciplines and experience levels. Thermo Fisher has evolved the popular Talos transmission electron microscope (TEM) design, culminating in the Thermo Scientific Talos 12 TEM, making leading-edge sample analysis more accessible than ever for biological research, pathology and drug development. TEM systems often require highly skilled specialists, but Talos 12 lowers those requirements with new enhancements to improve ease of use while maintaining high quality imaging with high reproducibility. ]]> https://biospectrumindia.com/news/117/26424/qiagen-expands-ngs-portfolio-with-launch-of-qiaseq-xhyb-long-read-panels.html https://biospectrumindia.com/news/117/26424/qiagen-expands-ngs-portfolio-with-launch-of-qiaseq-xhyb-long-read-panels.html Wed, 23 Jul 2025 00:00:00 +0530 Qiagen has announced the launch of its new QIAseq xHYB Long Read Panels, a suite of target enrichment solutions designed to unlock long-read sequencing of genomically complex regions. This new offering strengthens Qiagen’s position as a provider of differentiated solutions for use on any next-generation sequencing (NGS) platforms spanning both short- and long-read technologies. The new Qiagen panels are optimized for use with native long-read platforms, including from PacBio (NASDAQ: PACB), and designed to enable researchers to capture a broader spectrum of genomic variation. Applications include HLA typing, repeat expansion analysis, and the detection of structural variants – areas where short-read sequencing have been shown to have challenges. The launch comes as long-read sequencing gains momentum in areas such as translational and clinical research. Unlike synthetic long-read or short-read technologies, native long-read sequencing provides greater insight into complex genomic regions designed to improve accuracy in haplotype phasing, repeat detection and variant resolution. Qiagen’s expanded portfolio now allows researchers to choose between short- and long-read sequencing – or combine them – depending on their sample type and research objectives. Qiagen’s end-to-end NGS solutions empower genomic discovery across research and clinical settings. The portfolio integrates robust extraction kits and instruments for diverse and challenging sample types with dedicated target enrichment panels and streamlined library preparation and quality control automation.  ]]> https://biospectrumindia.com/news/117/26370/agilent-launches-infinitylab-pro-iq-series-mass-detectors-in-india.html https://biospectrumindia.com/news/117/26370/agilent-launches-infinitylab-pro-iq-series-mass-detectors-in-india.html Fri, 11 Jul 2025 00:00:00 +0530 Agilent Technologies has launched its InfinityLab Pro iQ Series mass detectors in India. The highly anticipated series, designed for next-generation liquid chromatography-mass detection (LC-MS), is poised to transform how Indian scientists detect and analyze impurities, trace contaminants, and complex biomolecules with unprecedented ease and sensitivity. The InfinityLab Pro iQ Series, comprising the Pro iQ and Pro iQ Plus, represents a significant leap forward in LC-mass detection. These intelligent, compact systems are designed to meet the evolving needs of modern analytical laboratories. They offer triple quadrupole-level sensitivity within a single quadrupole system, enabling highly sensitive and accurate detection. The systems incorporate smart automation features that ensure ease of use and consistent performance across workflows. Additionally, they integrate seamlessly with Agilent’s InfinityLab LC portfolio and the OpenLab software suite, creating a unified and efficient analytical environment. Together, these capabilities empower users to manage a wide range of workflows, including impurity profiling, biomolecule characterization, trace-level detection, and mass-based purification. The systems are equally effective for small molecule analysis and for complex biologics such as oligonucleotides, peptides, and intact proteins. “With the launch of the InfinityLab Pro iQ Series in India, Agilent is reaffirming its commitment to delivering cutting-edge solutions that empower scientists to achieve greater insight and efficiency. The Pro iQ Series makes high-performance mass detection more accessible than ever, empowering Indian labs to move faster, with greater confidence in their data, no matter what they’re analysing” said Nandakumar Kalathil, Country General Manager, Agilent India.   ]]> https://biospectrumindia.com/news/117/26343/bio-rad-labs-announces-launch-of-four-new-droplet-digital-pcr-platforms.html https://biospectrumindia.com/news/117/26343/bio-rad-labs-announces-launch-of-four-new-droplet-digital-pcr-platforms.html Mon, 07 Jul 2025 00:00:00 +0530 Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, has announced the launch of four new Droplet Digital™ PCR (ddPCR™) platforms. The newly introduced instruments include Bio-Rad’s QX Continuum™ ddPCR system along with the QX700™ series of ddPCR platforms acquired as part of the company’s recently completed acquisition of digital PCR developer Stilla Technologies. Together with Bio-Rad’s existing line of QX200™ and QX600™ ddPCR systems, the expanded product portfolio, including over 400,000 assays, offers the most comprehensive line of digital PCR products for life science research and diagnostic applications. The end-to-end solutions feature industry-leading absolute quantification, high precision, and advanced multiplexing capabilities, combined with streamlined and simplified workflows. The QX Continuum™ ddPCR system is designed for translational research applications. It features qPCR-like workflow offering simplicity, performance and flexibility in an all-in-one configuration with four-color multiplexing and up to eight discrete thermal profiles per plate. The QX700™ series consists of three new ddPCR instruments designed for academic research, environmental testing, cell and gene therapy, and biopharma quality control workflows. The systems enable seven-color multiplexing, capacity to process over 700 samples per day, with minimal input volume, continuous loading capability, and easy-to-use software for streamlined data interpretation. ]]> https://biospectrumindia.com/news/117/26252/ecolab-life-sciences-unveils-new-bioprocessing-purification-resin.html https://biospectrumindia.com/news/117/26252/ecolab-life-sciences-unveils-new-bioprocessing-purification-resin.html Mon, 16 Jun 2025 00:00:00 +0530 US-based Ecolab Life Sciences has launched an innovative new resin to help achieve cost savings and optimise operations throughout the antibody manufacturing process. Purolite™ AP+50 is an affinity chromatography resin with a 50-micron bead size offering the highest dynamic binding capacity of the AP resin platform while providing excellent durability for monoclonal antibody capture. It also leverages Ecolab’s patented Jetted resin bead manufacturing technology, an innovative approach that enables lot-to-lot consistency and shorter lead times. It is the latest addition to Ecolab’s robust Purolite Resin affinity toolbox which helps biopharmaceutical companies and Contract Development and Manufacturing Organisations solve complex purification challenges. “The ability to effectively improve process economics while maintaining purity is the gold standard of resin purification. As pharmaceutical and biotech companies seek to increase savings and improve business continuity, they are requiring innovative solutions to accelerate and de-risk manufacturing,” said Meeta Gulyani, senior vice president and general manager, Ecolab Bioprocessing. Purolite AP+50 resin joins Ecolab’s full suite of purification resins including the recently launched Purolite DurA Cycle™ A50 for longer lifetimes and Purolite 70 CH1 which targets complex antibody fragments. Together, they support process intensification strategies and cost of goods reduction, which are critical in late-phase, large-scale manufacturing. The announcement of Ecolab’s latest resin follows news of the opening of its newest Bioprocessing Applications Lab in King of Prussia, Pennsylvania.   ]]> https://biospectrumindia.com/news/117/26201/vfl-sciences-partners-with-cytosurge-ag-to-bring-fluidfm-omnium-platform-to-india.html https://biospectrumindia.com/news/117/26201/vfl-sciences-partners-with-cytosurge-ag-to-bring-fluidfm-omnium-platform-to-india.html Wed, 04 Jun 2025 00:00:00 +0530 Chennai-based VFL Sciences has entered a partnership with Cytosurge AG to offer the FluidFM® OMNIUM platform, a semi-automated single-cell manipulation system for non-destructive injection and extraction, compatible with single-cell RNA analysis and advanced gene editing techniques. With the blend of its products and partnered products, VFL Sciences has positioned itself as a complete solution provider for several workflows in life science laboratories. Dr Magid Haddouchi, Chief Commercial Officer at Cytosurge, stated, “India is one of the fastest-growing markets for scientific instruments, and we are excited to cooperate with VFL Sciences to grow our business further. With their experienced team, VFL Sciences will be your go-to partner for FluidFM OMNIUM expertise, support, and solutions, especially within Pharma, Biopharma, and Cell and Gene Therapy laboratories across India.” Vancheeswaran Sankaranarayanan, Managing Director of VFL Sciences, emphasised, “Our collaboration with Cytosurge brings Indian researchers access to world-leading single-cell analysis technology. We strongly believe that FluidFM technology’s global reputation in single-cell analysis will enable us to offer our customers the best solutions for their research, helping them gain deeper insights into cellular behavior, improve experimental accuracy, and accelerate innovation across the life sciences.” ]]> https://biospectrumindia.com/news/117/26196/thermo-fisher-launches-cutting-edge-solutions-for-omics-biopharma-and-environmental-workflows.html https://biospectrumindia.com/news/117/26196/thermo-fisher-launches-cutting-edge-solutions-for-omics-biopharma-and-environmental-workflows.html Tue, 03 Jun 2025 00:00:00 +0530 Thermo Fisher Scientific has unveiled state-of-the-art solutions at the annual American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, held in the US. These next-generation instruments and software offerings represent a paradigm shift in analytical performance – designed to reveal complex biological processes and critical insights into disease mechanisms that can transform multiomics, biopharma, environmental and food safety research. The company has introduced two mass spectrometry instruments that deliver unrivaled analytical performance and speed to uncover complex biological processes that could lead to advancements in precision medicine and significant insights for complex diseases like Alzheimer’s and cancer. The company has also unveiled the Thermo Scientific™ OptiSpray™ technology (as seen in the image) to empower omics researchers of all experience levels to generate reliable, high-quality LC-MS data with ease and expedite critical discoveries. As laboratories work to boost productivity and efficiency, the demand has never been greater for software that seamlessly connects data, applications, and instruments. Thermo Fisher has introduced several enhancements to its connected technology offerings to meet the needs of scientists today, providing advanced applications and critical compliance across research settings from life science discovery to improved water quality testing. For instance, Thermo Scientific™ Chromeleon™ 7.4 software offers the first scalable, networked software platform to fully support targeted, quantitative MS workflows across Thermo Fisher’s instruments, such as the Thermo Scientific Stellar MS. Thermo Scientific™ Proteome Discoverer™ 3.3 software now supports targeted proteomics data and automated processing of fractions with the Thermo Scientific Ardia™ Platform. Also, the Thermo Scientific™ Compound Discoverer™ 3.5 update includes algorithm and detection advancements to improve lipid application support while integrating the advanced Thermo Scientific™ Mass Frontier™ 8.1 software’s algorithm, enhancing in-silico fragmentation prediction. ]]> https://biospectrumindia.com/news/117/26194/sciex-sets-new-standard-in-accurate-mass-quantitation-with-zenotof-8600-system.html https://biospectrumindia.com/news/117/26194/sciex-sets-new-standard-in-accurate-mass-quantitation-with-zenotof-8600-system.html Mon, 02 Jun 2025 00:00:00 +0530 Sciex, a global leader in life science analytical technologies and operating company of Danaher Corporation, has launched the ZenoTOF 8600 system, setting a new standard in accurate mass quantitation. The system is competitive in identification, superior in quantitation, and enhances structural understanding so scientists can now confidently quantify thousands of species from complex samples in short acquisition times. The ZenoTOF 8600 system brings sensitive quantitation and decades of SCIEX leadership in triple quad innovation to the ZenoTOF portfolio. Innovations include: The OptiFlow Pro source, DJet ion guide, and QJet ion guide – Enables the system to generate and transmit more ions. When combined with the Zeno trap, this facilitates 10x improvement in sensitivity, compared to the ZenoTOF 7600+ system. Mass Guard technology, introduced last year on the Sciex 7500+ system – Protects the system from contamination and increases uptime. New optical detector – Allows the system to operate effectively at higher ion currents. ZT Scan DIA 2.0 – Covers a larger mass range so scientists can now quantify what was previously a struggle to identify – across all omics disciplines. ZT Scan DIA 2.0 is a transformation of the most comprehensive Sciex DIA approach. To match the data processing needs of the ZenoTOF 8600 system, the new Sciex OS software version 4.0 enhances operability with speed and automation. Automated workflow improvements and progressive software functionalities establish the benchmark for efficiency, accuracy, and precision. This builds on the Sciex OS ecosystem, to seamlessly connect innovations in hardware and software processing. A new software collaboration this year includes that with MS-Dial, an open-source software platform designed for untargeted metabolomics and lipidomics analysis.  ]]> https://biospectrumindia.com/news/117/26181/waters-introduces-bioresolve-protein-a-affinity-columns-to-accelerate-antibody-titer-measurement.html https://biospectrumindia.com/news/117/26181/waters-introduces-bioresolve-protein-a-affinity-columns-to-accelerate-antibody-titer-measurement.html Thu, 29 May 2025 00:00:00 +0530 Waters Corporation has announced the launch of BioResolve™ Protein A Affinity Columns with MaxPeak™ Premier Technology, which enable precise titer measurements. This launch is the first affinity chromatography pillar that Waters has brought to market. This is a groundbreaking step as the company continues to bring new products to market that address the unmet need in the separation of large molecules. The new pillars enable earlier access to results in upstream bioprocessing, faster method optimisation in downstream biologics development, and a new level of flexibility in the discovery, optimization and manufacturing of antibody-based drugs. One of the biggest bottlenecks in the development of biotherapeutics such as monoclonal antibodies is the time it takes to identify and optimize a suitable cell line for antibody production," said Dr Udit Batra, President and Chief Executive Officer of Waters Corporation. "We solved this problem by developing a novel, highly efficient particle with an immobilized protein A surface and combining it with the MaxPeak Premier hardware, resulting in the most sensitive protein A column on the market." BioResolve Protein A Affinity Columns are designed to deliver up to 7x improvement in sensitivity compared to the market leader. The novel, non-porous 3.5 μm particles enable accurate quantification of antibody titers at lower concentrations and with fewer samples. In addition, the columns have been designed to be coupled with size exclusion chromatography columns to measure titer concentrations and aggregate analysis in a single run on any LC system. ]]> https://biospectrumindia.com/news/117/26175/agilent-unveils-next-generation-in-lc-mass-detection-the-infinitylab-pro-iq-series.html https://biospectrumindia.com/news/117/26175/agilent-unveils-next-generation-in-lc-mass-detection-the-infinitylab-pro-iq-series.html Wed, 28 May 2025 00:00:00 +0530 Agilent Technologies Inc. has announced the launch of its latest innovation in liquid chromatography (LC)-mass detection: the Agilent InfinityLab Pro iQ Series. This groundbreaking series includes the InfinityLab Pro iQ and the InfinityLab Pro iQ Plus, each tailored with distinct features and capabilities to meet the diverse analytical needs of modern laboratories. These advanced, intelligent systems are particularly well-suited for analyzing essential molecules such as therapeutic small molecules, oligonucleotides, peptides, and proteins. The Pro iQ Series is designed to serve a broad range of end markets, including pharmaceutical and biopharmaceutical industries, academic and government research institutions, environmental testing labs, food safety organisations, and the chemical and specialty materials sector. With its precision, sensitivity, and intelligent design, the series supports applications such as mass confirmation, impurity profiling, biomolecule characterisation, trace contaminant detection, and compound purification, empowering scientists to achieve high-quality, reliable results in both routine and advanced analytical workflows. The Pro iQ Series delivers exceptional performance and sensitivity, making it ideal for monitoring complex biomolecules and detecting impurities. Whether analysing therapeutic small molecules, oligonucleotides, peptides, or proteins, the systems provide robust, high-resolution data to ensure accuracy, safety, and stability. The series also enables mass-based purification, allowing precise isolation of target compounds for downstream applications. The Pro iQ Plus system is engineered for high-end applications that demand ultimate sensitivity and performance. With an expanded mass range of m/z 2–3,000 and enhanced sensitivity through Agilent Jet Stream (AJS) technology, it supports both routine and trace-level detection of small and large molecules. These capabilities make it especially valuable in advanced R&D environments where extended analytical performance is critical. ]]> https://biospectrumindia.com/news/117/26153/thermo-fisher-introduces-next-generation-trunarc-handheld-narcotics-analysers-.html https://biospectrumindia.com/news/117/26153/thermo-fisher-introduces-next-generation-trunarc-handheld-narcotics-analysers-.html Sat, 24 May 2025 00:00:00 +0530 Thermo Fisher Scientific, the world leader in serving science, has introduced the Thermo Scientific™ TruNarc™ Delta and Tau Handheld Narcotics Analysers to help communities combat known and emerging narcotics and illicit substances. With touchless technology and an expanded chemical library, the user-friendly devices empower frontline law enforcement officials to identify more than 1,200 substances in the field, including stimulants, depressants, hallucinogens and analgesics – even at low concentrations or in mixtures – in seconds. The new TruNarc analysers build on the first generation with an updated industrial design, improved and modernized user interface, and performance enhancements that enable faster results. Automated record keeping generates documentation with complete scan data, including time-and-date stamps, to expedite prosecution and secure legal integrity. As drug substances continue to evolve and become harder to identify, the on-device chemical library of the TruNarc analyser is updated regularly to keep pace with new and emerging illicit drug threats.  Richard McCartney, President of chemical analysis at Thermo Fisher Scientific said, “As the opioid crisis persists, there’s a clear need for enhanced tools that better support public safety. By building on our proven technology, we are equipping those in the field with lab-quality tools that are durable enough to be used in a variety of environments.” ]]> https://biospectrumindia.com/news/117/26085/waters-integrates-multi-angle-light-scattering-detectors-with-empower-software.html https://biospectrumindia.com/news/117/26085/waters-integrates-multi-angle-light-scattering-detectors-with-empower-software.html Tue, 06 May 2025 00:00:00 +0530 Waters Corporation has announced that its Empower software now supports biologics data collection and quality control (QC) analysis of multi-angle light scattering (MALS) and refractive index (RI) instruments in its Wyatt Technology portfolio. This integration expands the scope of critical quality attributes that a biopharmaceutical laboratory can manage with Empower Software. In addition, this advancement simplifies the process and digital footprint of collecting and submitting compliant data to regulatory authorities – from biologic drug development to quality control – and saves customers up to six months of software validation time. Empower Software is the industry's most established and compliant chromatography data system (CDS) deployed globally, submitting data for more than 80% of novel medicines to regulatory authorities. The new integration enables the use of MALS techniques in quality control for biotherapeutics, improving efficiency and readiness to comply with Good Manufacturing Practices (GMP) while reducing the amount of training required for end-users in compliant environments. The integration of the DAWN, miniDAWN and OptiLab detectors enables the measurement of more critical quality characteristics of peptides and proteins in a single pass, reducing analysis time by 20% and providing earlier insights into the stability, safety and efficacy of biologics. ]]> https://biospectrumindia.com/news/117/26077/agilent-unveils-transformative-seahorse-xf-flex-analyser.html https://biospectrumindia.com/news/117/26077/agilent-unveils-transformative-seahorse-xf-flex-analyser.html Mon, 05 May 2025 00:00:00 +0530 Agilent Technologies Inc. has announced release of the new Seahorse XF Flex Analyser, a high-performance, 24-well system designed to expand real-time metabolic analysis into optimised 3D tissue and organoid workflows, along with dedicated consumables and kit."The new Seahorse XF Flex Analyser has significantly enhanced our research capabilities. Its 24-well user-friendly design allows us to focus on experiments rather than struggling with equipment, while its heightened sensitivity makes it easier to detect subtle changes in metabolic activity in 2D and 3D cellular models. This efficiency and versatility, especially in studying brain tissue, has made it an invaluable tool for advancing our understanding of metabolism,” stated Dr Yvonne Couch, Associate Professor of Neuroimmunology at the University of Oxford, UK. In combination with the Seahorse XF Flex Analyser, the optimised Seahorse XF Flex tissue workflow includes several key components designed to enhance real-time metabolic analysis in live tissue models. It features the Seahorse XF Flex 3D Capture Microplate, essential for capturing 3D tissue samples, and the Seahorse XF 3D Mito Stress Test Kit, used to measure mitochondrial function in these models. The workflow also incorporates a precision-cut vibratome, a tool that allows for the creation of consistent and smooth tissue sections, crucial for accurate metabolic analysis. Additionally, the intuitive XF software simplifies assay setup, automates data quality control, and transforms data into actionable insights with minimal effort. These components work together to provide a comprehensive solution for researchers, ensuring higher sensitivity and consistency in their measurements.  ]]> https://biospectrumindia.com/news/117/26063/qiagen-expands-digital-pcr-portfolio-with-new-lentivirus-solutions.html https://biospectrumindia.com/news/117/26063/qiagen-expands-digital-pcr-portfolio-with-new-lentivirus-solutions.html Thu, 01 May 2025 00:00:00 +0530 Qiagen has announced the expansion of its cell and gene therapy (CGT) portfolio with an enhanced digital PCR (dPCR) workflow that now includes solutions for lentivirus-based applications, commonly used in the production of advanced treatments such as chimeric antigen receptor T-cell (CAR-T), a personalised form of cancer immunotherapy. This expanded offering supports standardised, high-precision quality control (QC) workflows and strengthens the position of QIAGEN as a trusted partner for quality control, supporting biotech and biopharma companies, Contract Development and Manufacturing Organisations (CDMO) and therapy developers in CGT manufacturing. The QIAcuity RCL Quant Kit detects replication-competent lentivirus (RCL), a key safety concern in lentiviral vector production. The kit uses clear step-by-step protocols to find even small amounts of RCL, helping therapy developers meet regulations and keep treatments safe. The new QIAcuity CGT dPCR assays, including eight different wet-lab verified lentiviral targets, are designed for viral vector genome titration (measuring the amount of therapeutic virus particles) and vector copy number (VCN) determination (counting how many copies of a gene are inserted into each cell). The new CGT Lentivirus Lysis Kit and protocol, combined with QIAcuity CGT dPCR assays, enables vector genome titer quantification with fewer hands-on steps, enhanced accuracy and repeatability.  ]]> https://biospectrumindia.com/news/117/25928/thermo-fisher-scientific-launches-krios-5-cryo-transmission-electron-microscope.html https://biospectrumindia.com/news/117/25928/thermo-fisher-scientific-launches-krios-5-cryo-transmission-electron-microscope.html Thu, 03 Apr 2025 09:00:00 +0530 Thermo Fisher Scientific, the world leader in serving science, has introduced the Thermo Scientific Krios 5 Cryo-Transmission Electron Microscope (TEM). This next-generation, atomic-resolution platform leverages enhanced optics and AI-enabled automation to study molecular structures and interactions at a throughput and fidelity that was previously unattainable. In the rapidly evolving field of structural biology, single particle analysis (SPA) and cryo-electron tomography (cryo-ET) are powerful techniques that allow scientists to better understand the intricacies of biology, providing atomic-level insights that reveal how viruses, proteins and cells work. The Krios 5 Cryo-TEM optimises productivity and performance to enhance these techniques. With a throughput improvement of up to 25% compared to previously released models, the Krios 5 enables 3D visualisation of proteins, as well as their interactions and dynamics within the biological cell. Other Krios 5 advantages include AI-powered experimental set-up and upgraded data acquisition. For the cryo-ET workflow, the innovative vacuum capsule transfer helps prevent contamination of samples. Collectively, these enhancements build on Thermo Fisher’s cryo-EM legacy with a new generation of Krios that will enable researchers to pioneer new treatments and advance drug discovery. ]]> https://biospectrumindia.com/news/117/25923/waters-expands-alliance-is-bio-hplc-product-line-with-photodiode-array-detector.html https://biospectrumindia.com/news/117/25923/waters-expands-alliance-is-bio-hplc-product-line-with-photodiode-array-detector.html Wed, 02 Apr 2025 00:00:00 +0530 Waters Corporation has announced the expansion of the Alliance iS Bio HPLC product line with integrated photodiode array (PDA) detection, advancing the capabilities of the next-generation intelligent HPLC platform designed for development and Quality Control (QC) laboratories. The Alliance iS HPLC Platform has been purposefully designed to simplify laboratory workflows by reducing the risk of out-of-specification results and the need for troubleshooting. Default system parameters provide over threefold improvement in day-to-day reproducibility and reduce carryover by up to two orders of magnitude, compared to other systems on the market. Additionally, with MaxPeak Premier columns, the Alliance iS Bio HPLC System enhances out-of-the-box sensitivity by up to 80 times compared to traditional systems and columns. Waters now offers four configurations of the Alliance iS HPLC Platform to support routine quantitative analysis and expanded spectral analysis of small and large molecules in development and QC. All configurations are controlled by the compliance-ready Waters Empower Chromatography Data System, which enables laboratories to collect, manage, and report chromatography test results. The platform also supports connectivity with laboratory information management systems (LIMS) to help high-volume QC labs manage operational risk, mitigate disruptions, and increase overall productivity.  ]]> https://biospectrumindia.com/news/117/25878/thermo-fisher-unveils-one-lambda-hybritype-hla-plus-typing-flex-kit.html https://biospectrumindia.com/news/117/25878/thermo-fisher-unveils-one-lambda-hybritype-hla-plus-typing-flex-kit.html Mon, 24 Mar 2025 00:00:00 +0530 Thermo Fisher Scientific has launched the One Lambda HybriType HLA Plus Typing Flex kit. This next-generation sequencing (NGS) hybrid capture assay featuring a probe-based design that optimises read balance and uniformity is designed to provide flexibility in testing configuration and coverage, supporting human leukocyte antigen (HLA) genotyping analysis across various sample types, including whole blood and buccal swabs.    This testing kit aims to enable customers to perform deeper research into the major histocompatibility complex (MHC) that can impact various evolving conditions. Its simple workflow combined with One Lambda TypeStream Visual NGS Software enables rapid automated analysis.  Its flexible content and extensive gene coverage may minimize ambiguity, delivering results with ≥99.8% concordance. The streamlined workflow, taking less than 5.5 hours with under 2.5 hours of hands-on time, combined with One Lambda TypeStream Visual NGS Software, enables rapid automated analysis.  “We developed HybriType to enable our customers to perform deeper research into the major histocompatibility complex (MHC), a genetically rich region that plays a key role in histocompatibility and immunogenetics,” said Tina Liedtky, president, Transplant Diagnostics, Thermo Fisher Scientific. “As our knowledge of the human immune system and how the MHC may impact various conditions continues to evolve, we’re committed to providing our customers with the tools they need to further our collective understanding.”     ]]>